William Debell, MD
Endocrinology, Diabetes & Metabolism · Tuscaloosa, ALNPI 1184791329
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $138,227 of the $161,190 with a category attached, or 85.8%. 43 manufacturers reported payments, led by Novo Nordisk at 48.1% of the total. Reporting peaked in 2020 at $55,330 and has fallen 88.2% since, to $6,531 in 2025. Among endocrinology, diabetes & metabolism clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,049 payments — averaging $153.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$77K
- Dexcom, Inc.$46K
- Tandem Diabetes Care, Inc.$19K
- Johnson & Johnson$7K
- Lilly USA, LLC$2K
- Sanofi-aventis U.S. LLC$1K
- plus $8K from 37 others
What the payments were for
- Consulting fees$1,9151%
- Speaking & faculty fees$138,22786%
- Travel & lodging$4,2893%
- Food & beverage$15,86910%
- Education$8901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$48,972
- Ozempic$25,394
- DEXCOM G7 GSS (161)$23,825
- DEXCOM G6 TRANSMITTER$16,058
- t:slim X2 insulin pump$10,750
- t-slim insulin pump$7,950
- INVOKANA$7,020
- DEXCOM STELO GLUCOSE BIOSENSOR$6,434
- DEXCOM CGM$2,663
- DEXCOM G6 CGM SYSTEM$2,200
- iLet Bionic Pancreas$440
- Trinity ELITE$125
- Saxenda$123
- Korlym$103
How this compares
$161,190 in reported general payments places this provider in the 90th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 183 | $226,111 |
| JardianceEmpagliflozin | 146 | $148,058 |
| MounjaroTirzepatide | 118 | $138,254 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $68,175 |
| JanuviaSitagliptin Phosphate | 76 | $67,178 |
| EliquisApixaban | 77 | $64,868 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $59,619 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $41,530 |
| Tresiba Flextouch U-100Insulin Degludec | 77 | $41,247 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $40,138 |
| Humalog Kwikpen U-100Insulin Lispro | 67 | $25,292 |
| TrulicityDulaglutide | 24 | $24,553 |
| JanumetSitagliptin Phos/Metformin Hcl | 23 | $22,888 |
| HumalogInsulin Lispro | 74 | $20,757 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 161 | $19,427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Fiasp | $77,475 | $252,099252 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin 70-30, Lyumjev | $1,989 | $191,762251 claims |
| Boehringer IngelheimJardiance, Tradjenta | $312 | $154,176158 claims |
| MerckJanuvia, Janumet | $380 | $90,06699 claims |
| PfizerEliquis | $119 | $64,86877 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $1,315 | $26,07367 claims |
| AbbVieLinzess, Synthroid | $780 | $20,27671 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $34 | $12,77623 claims |
| GSKTrelegy Ellipta | $14 | $9,05814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Tuscaloosa
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
- Judson MenefeeFairhope$168K
- Edison GoncalvesBirmingham$142K
- David BellIrondale$112K
- Bethany JacksonFlorence$90K
- Dwain WoodeHuntsville$78K
- Fernando BrilBirmingham$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.